
## Bhavatarini Vangamudi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11947830/publications.pdf Version: 2024-02-01



RHAVATARINI VANCAMUDI

#	Article	IF	CITATIONS
1	Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities. Journal of the American Chemical Society, 2021, 143, 4714-4724.	13.7	18
2	Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs. Nature Biomedical Engineering, 2018, 2, 822-830.	22.5	26
3	Identification and Optimization of Anthranilic Acid Based Inhibitors of Replication Proteinâ€A. ChemMedChem, 2016, 11, 893-899.	3.2	13
4	Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery. Epigenetics and Chromatin, 2015, 8, 37.	3.9	32
5	The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Research, 2015, 75, 3865-3878.	0.9	202
6	Diphenylpyrazoles as Replication Protein A Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 140-145.	2.8	18
7	Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A. Journal of Medicinal Chemistry, 2014, 57, 2455-2461.	6.4	49
8	Surface Reengineering of RPA70N Enables Cocrystallization with an Inhibitor of the Replication Protein A Interaction Motif of ATR Interacting Protein. Biochemistry, 2013, 52, 6515-6524.	2.5	19
9	Discovery of a Potent Inhibitor of Replication Protein A Protein–Protein Interactions Using a Fragment-Linking Approach. Journal of Medicinal Chemistry, 2013, 56, 9242-9250.	6.4	59
10	Discovery of Protein–Protein Interaction Inhibitors of Replication Protein A. ACS Medicinal Chemistry Letters, 2013, 4, 601-605.	2.8	27